Literature DB >> 8528265

Evidence for the polymorphic oxidation of debrisoquine and proguanil in a New Zealand Maori population.

S Wanwimolruk1, E L Pratt, J R Denton, S C Chalcroft, P A Barron, J R Broughton.   

Abstract

The genetic oxidation polymorphisms of debrisoquine and proguanil were studied in a New Zealand Maori population. A bimodal distribution was observed in the 0-4 h urinary debrisoquine/4-hydroxydebrisoquine metabolic ratio. Of 101 Maori subjects phenotyped, five subjects (5%) were identified as poor metabolizers of debrisoquine, according to criteria established in studies of Caucasian populations. The prevalence of the debrisoquine poor metabolizer phenotype in the Maori appears to be similar to that reported for the Caucasian populations, but higher than that found in Asian (non-Caucasian) populations. The distribution of proguanil:cycloguanil (PG:CG) ratios obtained from 43 Maori subjects was highly skewed. Using a PG:CG ratio of 10 as the cut-off point, three Maori subjects (7%) were classified as poor metabolizers of proguanil. The incidence of the poor metabolizer phenotype of proguanil oxidation of 7% seems to be higher in Maori compared with Caucasian populations, but this is lower than the usual ranges (15-35%) reported in Asian populations.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8528265     DOI: 10.1097/00008571-199508000-00002

Source DB:  PubMed          Journal:  Pharmacogenetics        ISSN: 0960-314X


  6 in total

Review 1.  Interethnic variation of CYP2C19 alleles, 'predicted' phenotypes and 'measured' metabolic phenotypes across world populations.

Authors:  I Fricke-Galindo; C Céspedes-Garro; F Rodrigues-Soares; M E G Naranjo; Á Delgado; F de Andrés; M López-López; E Peñas-Lledó; A LLerena
Journal:  Pharmacogenomics J       Date:  2015-10-27       Impact factor: 3.550

Review 2.  CYP2C19 and CYP2D6 genotypes in Pacific peoples.

Authors:  Nuala A Helsby
Journal:  Br J Clin Pharmacol       Date:  2016-08-26       Impact factor: 4.335

3.  Relationship between proguanil metabolic ratio and CYP2C19 genotype in a Caucasian population.

Authors:  J M Hoskins; G M Shenfield; A S Gross
Journal:  Br J Clin Pharmacol       Date:  1998-11       Impact factor: 4.335

4.  Concordance between proguanil phenotype and CYP2C19 genotype in Chinese.

Authors:  Janelle M Hoskins; Gillian M Shenfield; Annette S Gross
Journal:  Eur J Clin Pharmacol       Date:  2003-09-12       Impact factor: 2.953

5.  Phenotyping and genotyping of CYP2C19 using comparative metabolism of proguanil in sickle-cell disease patients and healthy controls in Nigeria.

Authors:  Olufunmilayo E Adejumo; Taiwo R Kotila; Adeyinka G Falusi; Boladale O Silva; Jacinta N Nwogu; Pius S Fasinu; Chinedum P Babalola
Journal:  Pharmacol Res Perspect       Date:  2016-08-22

6.  A high incidence of polymorphic CYP2C19 variants in archival blood samples from Papua New Guinea.

Authors:  Huai-Ling Hsu; Kathryn J Woad; D Graeme Woodfield; Nuala A Helsby
Journal:  Hum Genomics       Date:  2008-09       Impact factor: 4.639

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.